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Abstracts / Urological Science 26 (2015) S36eS49S48benign bladder, ureteral or cortical tissues (chi-square test, p ¼ 0.0073).
There is a moderate correlation for urine 3-HAA measurement based on
between HPLC and the biosensor assays (r2¼ 0.47, p¼ 0.0033). Besides, the
3-HAA content within the cultured media of TCCSUP and BFTC905
measured with biosensors signiﬁcantly increased with incubation time
(p < 0.0001). Finally, Patients with urothelial carcinoma of bladder and
upper tract have higher urine 3-HAA levels than those without recurrence
or benign urological disease, such as BPH, or hernia (unpaired t-test,
p ¼ 0.028), except for urolithiasis.
Conclusion: The integrated biosensor exhibited a modest accuracy in
urine 3-HAA detection. Both of urothelial carcinoma of urinary bladder and
upper tract exhibited higher IDO expression and its metabolite 3-HAA in
urine.
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AKT ACTIVITY IN BLADDER CANCER CELL
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Cheng-Hsin Rehabilitation Medical Center, Taipei, Taiwan; 2 Institute of
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Purpose: Bladder cancer, a malignant urinary system tumor, is in the ninth
position of the international cancer charts. The cancer shows a highly
recurrent rate that is around 50%~60%. Therefore, investigating a new
therapy to improve the curing rate of the cancer is important. Nowadays,
Bacillus- Calmette-Guerin (BCG) immune therapy is the most common
way for the treatment of bladder cancer. However, there are around 20 %
patients unable to get any beneﬁt from this, and the main mechanism of
the effect of BCG is still unclear. Since BCG treatment have reported, that
macrophages might be recruited into the bladder to induce cancer cell
death by the pro-inﬂammatory response, we further study the mechanism
of BCG. We used lipopolysaccharide to induce macrophage Raw264.7 for
the generation of condition medium (CM-LPS). Our results demonstrated
that CM-LPS might cause cell death via a caspase-dependent manner in
MBT2 bladder cancer cells. As compared with CM-LPS, TNF-a involved the
cell death. Moreover, TNF-a-induced AKT activation was found in MBT2
cell, implying that the activating AKT may have anti-apoptotic activity.
Since ceramide is generated after inﬂammation, we propose that ceramide
may increase TNF-a-induced cell death in bladder cancer.
Materials and methods: MBT-2 cell were treated with different concen-
trations of TNF-a, ceramide, and then the cell death were analyzed with
MTS analysis and Hoechst3334.2 staining for chromatin condensation. The
mechanisms of the cell death of TNF-a combining with ceramide were
investigated by using western blotting to detect AKT activation.
Results: In our study exhibits that TNF-a had slightly to induce MBT2 cell
death. Moreover, using western blot to analyze AKT expression in bladder
cell were exhibited that ceramide decrease AKT activation. In our study,
ceramide reduced AKT activity, promoted mitochondrial disruption and
dephosphorylated Bad, a BH3 containing pro-apoptotic protein. TNF-a
combining with ceramide exhibited chromatin condensation and DNA
fragmentation by Hochest33342 staining assay. Our ﬁndings suggest that
CM-LPS has the cytotoxic activity via ceramide and TNF-a to elicit cell
death in MBT2 cell.
Conclusions: In this study, we suggest that ceramide were promoted TNF-
a-induced cell death via decreasing AKT activity in bladder cancer cell.
These results are demonstrated that ceramide-mediated AKT inactivation
may play an important role in BCGeinduced cell death in MBT2 bladder
cancer cells. Our ﬁndings suggest that improvement of bladder cancer
therapy will be able to decrease the activation of AKT.
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TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA: CASE
SERIES STUDY IN SINGLE HOSPITAL EXPERIENCE
Tzu-Hsiang Wu 1, Yi-Chia Lin 1,2, Te-Fu Tsai 1,2, Guang-Dar Juang 1,2, Chung-
Hsin Yeh 1,2, Yi-Hung Cheng 1,2, Kuang-Yu Chuo 1, Hung-En Chen 1, Thomas
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Memorial Hospital, Taipei, Taiwan, ROC; 2Department of Urology, Fu Jen
Catholic University School of Medicine, Taipei, Taiwan, ROCPurpose: Treatment for metastatic renal cell carcinoma (mRCC) has
recently focused on targeted therapy including tyrosine kinase inhibitors
andmTOR inhibitors. Molecular-targeted therapies have been proved to be
effective treatment options. We herein report the outcomes of targeted
therapy for mRCC in our institution.
Materials and methods: From 2010 to 2015, 15 mRCC patients were
identiﬁed in our institute under targeted therapy with a diagnosis of
mRCC. Three targeted agents, namely temsirolimus, sunitinib, and ever-
olimus, were given for patient according to the clinical condition. Sunitinib
and Temsirolimus were served as ﬁrst-line treatment and Everolimus was
the secondeline treatment. Demographics, the interval between diagnosis
of metastasis and targeted therapy, the duration of targeted therapy, side
effects and complications after treatment were collected with a retro-
spective medical record review. Response rate were analyzed according to
RECIST criteria.
Results: Among the 15 patients, 9 were male and 6 were female. The mean
age was 70.3 (35-88) years old. Lung metastasis was noted in 80% (12/15)
of the patient, and other sites of metastasis were also noted, including
lymphnodes, liver, bone and adrenal gland. The mean interval between
diagnosis of metastasis and targeted therapy is 27.5 (1e78) days. The mean
duration of targeted therapy is 268.5 days with temsirolimus, 397.8 days
with sunitinib and 360.3 days with everolimus. The most common side
effect noted in targeted therapy is anemia (100%) in temsirolimus group,
hand-foot mouth syndrome (61.5%) and hypertension (61.5%) in sunitinib
group, and cough (50%) (without radiologic sign of interstitial pneumo-
nitis) in everolimus group. There were 2 patients (2/4) with disease
regression and 2 (2/4) with stationary disease under everolimus usage,
compared with 2 patients (2/12) with disease regression, 5 patients (5/12)
with progression disease and 5 patients in stationary status under suni-
tinib usage. One patient with temsirolimus usage was in disease pro-
gression, and the other was in stationary status.
Conclusion: Targeted therapy prolonged the life of mRCC patients with
tolerable outcome. In our series, the response rate of Everolimus is higher
than expected.
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Purpose: Radical nephroureterectomy (NU) with bladder-cuff excision has
been the traditional treatment for UTUC because of its high rate of recur-
rence. However, given the morbidity of nephrectomy and the risk of
developing chronic kidney disease (CKD) or dialysis-dependent renal
failure, a nephron-sparing approach may be preferable in selected
patients.
Materials and methods: We retrospectively analyzed 19 patients from
March 2006 to December 2014 at single center in Southern Taiwan who
underwent distal ureterectomy with reimplantation of ureter and
conﬁrmed to be ureter malignancy (urothelial carcinoma n ¼ 18, squa-
mous cell carcinoma n ¼ 1) on ﬁnal pathology. Outcome measures were
recurrence or distant metastasis, renal function preservation, time to
recurrence and overall survival.
Results: Total 19 patients, 13males, 6 females, andmean age are 69.3 years
old. There are no local recurrence, 9 bladder recurrence (47.4%), 3 distant
metastasis (15.8%), and 2 progression to radical nephroureterectomy
(10.5%). Pathological staging: Tis n¼ 1, Ta n¼ 3, T1 n¼ 2, T2 n¼ 6, T3 n¼ 5.
Low grade n ¼ 3, high grade n ¼ 12. Mean time to recurrence was 12.4
(3e24) months, and mean follow up time was 28.1 (1e90) months. Overall
survival rate is 73.7% (14/19), among them, 4 lost follow up, 1 expired.
Mean pre-op creatinine was 1.61 mg/dl, 1 yr post operation creatinine was
1.56mg/dl.
Conclusion: Distal ureterectomy with reimplantation surgery in our
experience is a feasible option for distal ureter tumor in selected patients
(chronic kidney disease, solitary kidney). Favorable post-operative
